Journal Mobile Options
Table of Contents
Vol. 16, No. 3, 2001
Issue release date: May–June 2001

Maternal Serum CA125 and CA15-3 Antigen Levels in Normal and Pathological Pregnancy

Bon G.G. · Kenemans P. · Verstraeten A.A. · Go S. · Philipi P.A. · van Kamp G.J. · van Geijn H.P. · van Vugt J.M.G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To evaluate the value of maternal serum CA125 and CA15-3 concentrations for discriminating pathological from normal pregnancies. Methods: Serum samples from 120 women, in whom pregnancy outcome was pathological, i.e. spontaneous abortion, fetal death, intrauterine growth retardation, chromosomal and structural abnormalities, and (pre)eclampsia, were assessed for CA125 and CA15-3 and compared with levels found in 350 women with a normal pregnancy outcome matched for age and duration of pregnancy. Results: Maternal CA125 serum values were significantly higher in the first and the third trimester of pregnancy (median 23.0 and 21.0 U/ml; p < 0.00001 and p < 0.001, respectively), compared to those in the second trimester (median 14.0 U/ml), but not significantly different from those obtained in pathological pregnancies. Maternal serum CA15-3 values were significantly higher during the third trimester (median 26.0 U/ml) compared to the first and second trimester of pregnancy (median 14.0 and 15.0 U/ml; p < 0.0001); CA15-3 serum levels in normal and pathological pregnancies showed no significant difference. Conclusion: Maternal serum levels of CA125 are higher during the first and third trimester of pregnancy. CA15-3 maternal serum levels are higher during the third trimester compared to the first and second trimester. Maternal CA125 and CA15-3 serum levels showed no relation with a pathological outcome of pregnancy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bon GG, Kenemans P, van Kamp GJ, Yedema CA, Hilgers J: Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med All Sci 1990;34:151–162.

    External Resources

  2. Seki K, Kikuchi Y, Uesato T, Kato K: Increased serum CA125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand 1986;65:583–585.

    External Resources

  3. Spitzer M, Kaushal N, Benjamin F: Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998;43:387–392.
  4. Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T: Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol 1989;160:563–566.

    External Resources

  5. Kenemans P, Bon G, Kessler A, Verstraeten A, van Kamp G: Technical and clinical evaluation of a new fully automated enzyme immunoassay for the detection of CA125, a multicenter study. Clin Chem 1992;38:1466–1471.
  6. Check JH, Nowroozi K, Winkel CA, Johnson T, Seefried L: Serum CA 125 levels in early pregnancy and subsequent spontaneous abortion. Obstet Gynecol 1990;742–744.
  7. Azogui G, Yaronovski A, Zohar S, Ben-Shlomo I: CA-125 is elevated in viable pregnancies destined to be miscarried: A prospective longitudinal study. Fert Steril 1996;65:1059–1061.
  8. Wenstrom KD, Owen J, Boots T: Second-trimester maternal serum CA-125 versus estriol in the multiple-marker screening for Down’s syndrome. Obstet Gynecol 1997;89:359–363.
  9. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, Schoemaker J: Fluctuations in CA125 and CA15-3 serum levels during spontaneous ovulatory cycles. Hum Reprod 1999;14:566–570.
  10. Milunsky A, Alpert E, Neff RK, Frigoletto FP: Prenatal diagnosis of neural tube defects. IV. Maternal serum alpha-fetoprotein screening. Obstet Gynecol 1980;55:60–66.

    External Resources

  11. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE: An association between low maternal serum alpha-fetoprotein and fetal chromosomal anomalies. Am J Obstet Gynecol 1984;148:886–891.

    External Resources

  12. Kenemans P, Verstraeten AA, van Kamp GJ, von Mensdorff-Pouilly S: The second generation CA 125 assays. Ann Med 1995;27:107–113.
  13. Jaworek D, Zepke D, Hauber R: Technical and clinical evaluation of a new automated CA 15-3 test; in Klapdor R (ed): Tumor associated antigens, oncogenes, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Cancer of the breast – State and trends in diagnosis and therapy. Munich, Zuckschwerdt, 1992, pp 259–263.
  14. Cuckle HS, Wald NJ, Thompson SG: Estimating a woman’s risk of having a pregnancy with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387–402.
  15. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr: CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703–707.
  16. Quirk JG, Brunson GL, Long CA, Bannon GA, Sanders MM, O’Brien TJ: CA-125 in tissues and amniotic fluid during pregnancy. Am J Obstet Gynecol 1988;159:644–649.

    External Resources

  17. Check JH, Vetter BH: A challenge to the concept of tubal reflux to explain the rise and fall of CA125 in serum during the first trimester. Human Reprod 1995;10:674–676.
  18. Lellé RJ, Henkel E, Leineman D, Goeschen K: Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 1989;27:137–142.

    External Resources

  19. Touitou Y, Darbois Y, Bogdan A, Auzéby A, Keusseoglou S: Tumour marker antigens during menses and pregnancy. Br J Cancer 1989;60:419–420.

    External Resources

  20. Braga VM, Pemberton LF, Duhig T, Gendler SJ: Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 1992;115:427–437.

    External Resources

  21. Braga VM, Gendler SJ: Modulation of MUC-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation. J Cell Sci 1993;105:397–405.
  22. Seppala M, Ruoslahti E: Radioimmunoassay of maternal serum alpha fetoprotein during pregnancy and delivery. Am J Obstet Gynecol 1972;112:208–212.

    External Resources

  23. van Lith JM, Mantingh A, De Bruijn WA: Maternal serum CA 125 levels in pregnancies with chromosomally-normal and -abnormal fetuses. Dutch Working Party on Prenatal Diagnosis. Prenat Diagn 1993;13:1123–1131.

    External Resources

  24. Spencer K, Muller F, Aitken DA: Amniotic fluid and maternal serum levels of CA125 in pregnancies affected by Down syndrome: A re-evaluation of the role of CA125 in Down syndrome screening. Prenatal Diagn 1997;17:701–706.
  25. Amin NS, Eladhami BH, Tahir SAJ: Evaluation of serum cancer antigen CA 125 in preeclampsia. Med Sci Res 1997;25:409–411.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50